Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	851.6	1,044	1,049	1,118	1,774	1,577
Revenue Growth (YoY)	-22.74%	-0.54%	-6.10%	-36.99%	12.45%	42.61%
Cost of Revenue	371.4	668.2	689.3	644.5	980.4	714.2
Gross Profit	480.2	375.4	360	473	793.2	863.1
Selling, General & Admin	233.3	298.7	356.7	339.5	348.7	304.1
Research & Development	63.8	63.8	105.8	182.9	-	-
Operating Expenses	362.2	427.6	528.1	582.3	407.2	363.9
Operating Income	118	-52.2	-168.1	-109.3	386	499.2
Interest Expense	-52.5	-71	-87.9	-37.3	-34.5	-31.3
Other Non Operating Income (Expenses)	85.2	13.1	8.9	-11.7	-3.7	4.7
EBT Excluding Unusual Items	150.7	-110.1	-247.1	-158.3	347.8	472.6
Merger & Restructuring Charges	-38.7	-55.9	-33.2	-51.4	-	-
Impairment of Goodwill	-	-	-218.2	-6.7	-41.7	-
Gain (Loss) on Sale of Assets	52.1	24.3	74.2	-	-	-
Asset Writedown	27.2	-	-306.7	-	-	-29
Other Unusual Items	-0.6	-1.2	-0.2	-2.6	-2.9	-31.7
Pretax Income	190.7	-142.9	-731.2	-219	303.2	411.9
Income Tax Expense	51.2	47.7	29.3	-7.4	83.7	106.1
Earnings From Continuing Operations	139.5	-190.6	-760.5	-211.6	219.5	305.8
Net Income	139.5	-190.6	-760.5	-211.6	219.5	305.8
Net Income to Common	139.5	-190.6	-760.5	-211.6	219.5	305.8
Net Income Growth	-	-	-	-	-28.22%	461.10%
Shares Outstanding (Basic)	54	53	51	50	54	53
Shares Outstanding (Diluted)	55	53	51	50	54	54
Shares Change (YoY)	5.75%	3.52%	2.20%	-7.39%	0.56%	2.67%
EPS (Basic)	2.59	-3.60	-14.85	-4.22	4.10	5.80
EPS (Diluted)	2.53	-3.60	-14.85	-4.22	4.06	5.68
EPS Growth	-	-	-	-	-28.52%	446.15%
Free Cash Flow	155	35.8	-257.9	-149.9	96.1	395
Free Cash Flow Per Share	2.81	0.68	-5.04	-2.99	1.78	7.34
Gross Margin	56.39%	35.97%	34.31%	42.33%	44.72%	54.72%
Operating Margin	13.86%	-5.00%	-16.02%	-9.78%	21.76%	31.65%
Profit Margin	16.38%	-18.26%	-72.48%	-18.93%	12.38%	19.39%
Free Cash Flow Margin	18.20%	3.43%	-24.58%	-13.41%	5.42%	25.04%
EBITDA	216.8	53.4	-47	15.7	504.2	609.2
EBITDA Margin	25.46%	5.12%	-4.48%	1.41%	28.43%	38.62%
D&A For EBITDA	98.8	105.6	121.1	125	118.2	110
EBIT	118	-52.2	-168.1	-109.3	386	499.2
EBIT Margin	13.86%	-5.00%	-16.02%	-9.78%	21.76%	31.65%
Effective Tax Rate	26.85%	-	-	-	27.61%	25.76%
Revenue as Reported	851.6	1,044	1,049	1,118	1,774	1,577

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q